The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation

(2014) Ramiro París et al.   CELL CYCLE

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death

(2011) Mark Wade et al.   CELL CYCLE

Phosphoinositide 3-kinase signaling overrides a G2phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage

(2011) Dipali Nimbalkar et al.   CELL CYCLE

Cancer stem cells and survival pathways

(2011) Dolores Hambardzumyan et al.   CELL CYCLE

Resist or die: FOXO transcription factors determine the cellular response to chemotherapy

(2011) Ana R. Gomes et al.   CELL CYCLE

Cancer and aging: More puzzles, more promises?

(2011) Mikhail V Blagosklonny et al.   CELL CYCLE

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

(2011) Arkaitz Carracedo et al.   CELL CYCLE

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

(2011) Mingxuan Xia et al.   CELL CYCLE

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

(2011) Teresa Palomero et al.   CELL CYCLE

The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior

(2011) Yan Liu et al.   CELL CYCLE

DNA damage-induced cell death is enhanced by progression through mitosis

(2011) Hanne Varmark et al.   CELL CYCLE

Mutant p53 rescue and modulation of p53 redox state

(2011) Vladimir J.N. Bykov et al.   CELL CYCLE

Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence

(2011) Zoya N. Demidenko et al.   CELL CYCLE

The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells

(2011) Angelina V. Vaseva et al.   CELL CYCLE

Upregulation of the CDC25A phosphatase downstream of the NPM/ALK oncogene participates in anaplastic large cell lymphoma enhanced proliferation

(2011) Anne Fernandez-Vidal et al.   CELL CYCLE

Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic deceleration

(2011) Mikhail V Blagosklonny   CELL CYCLE

The CML stem cell: Evolution of the progenitor

(2011) Scott A. Stuart et al.   CELL CYCLE

At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence

(2011) Zoya N. Demidenko et al.   CELL CYCLE

Rapamycin decelerates cellular senescence

(2011) Zoya N. Demidenko et al.   CELL CYCLE

Genomic instability en route to and from cancer stem cells

(2011) Linda Li et al.   CELL CYCLE

Targeting mTOR with rapamycin: One dose does not fit all

(2011) David A. Foster et al.   CELL CYCLE

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

(2011) Giovanni Ligresti et al.   CELL CYCLE

PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects

(2011) Vera P. Krymskaya et al.   CELL CYCLE

Growth stimulation leads to cellular senescence when the cell cycle is blocked

(2010) Zoya N. Demidenko et al.   CELL CYCLE

Targeting prostate cancer based on signal transduction and cell cycle pathways

(2010) John T. Lee et al.   CELL CYCLE

RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53

(2010) Sindy Sohr et al.   CELL CYCLE

Aging: ROS or TOR

(2010) Mikhail V Blagosklonny   CELL CYCLE

Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

(2010) Zhengping Zhuang et al.   CELL CYCLE

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

(2010) Meng Ling Choong et al.   CELL CYCLE

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

(2008) J A McCubrey et al.   LEUKEMIA

c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia

(2008) E D Lagadinou et al.   LEUKEMIA

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

(2008) F Chiarini et al.   LEUKEMIA

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

(2008) J A McCubrey et al.   LEUKEMIA

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

(2008) N Misaghian et al.   LEUKEMIA

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

(2008) L S Steelman et al.   ONCOGENE

Aging, Stem Cells, and Mammalian Target of Rapamycin: A Prospect of Pharmacologic Rejuvenation of Aging Stem Cells

(2008) Mikhail V. Blagosklonny   REJUVENATION RESEARCH